RLAY
$10.26
Relay Therapeutics, Inc.
Recent News
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest
Relay Therapeutics (RLAY) is back in focus after reporting a narrower than expected quarterly loss, higher year on year revenue, and securing FDA Breakthrough Therapy designation for its zovegalisib program in oncology. See our latest analysis for Relay Therapeutics. That backdrop has attracted fresh attention to the stock, with a 1 day share price return of 12.01% and a 30 day share price return of 34.12%. The 1 year total shareholder return is very large compared to its 3 and 5 year total...
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.51% and -52.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?